Background
allergic rhinoconjunctivitis
ALLERGIC RHINOCONJUNCTIVITIS
Edited by: Jamie Marie Orengo, Regeneron Pharmaceuticals, Inc., United StatesReviewed by: Sang Min Lee, Gachon University Gil Medical Center, Republic of Korea; Hideyuki Kawauchi, Shimane University, Japan†These authors have contributed equally to this workPediatric allergic rhinoconjunctivitis has become a public concern with an increasing incidence year by year. Conventional subcutaneous immunotherapy (SCIT) has long treatment time, high cost and poor compliance. The novel immunotherapy significantly shortens the course of treatment by directly injecting allergens into cervical lymph nodes, which can perform faster clinical benefits to children.